

Invasive Fungal Disease in Adults; Prophylaxis, Investigation, and Treatment - Microbiology Summary Clinical Guideline

Reference number: CG-T/2023/216

Primary prophylaxis

Yeast (*Candida* species)

- Antifungal prophylaxis is recommended when the incidence of *Candida* IFD is $\geq 6\%$. In specific populations of haematology and oncology patients, antifungal prophylaxis against *Candida* species is recommended.


Yeast (*Candida* species) and mould (*Aspergillus* species)

- Antifungal prophylaxis is recommended when the incidence of *Aspergillus* IFD is $\geq 6\%$. In specific populations of haematology and oncology patients, antifungal prophylaxis against *Candida* and *Aspergillus* species is recommended.

Primary prophylaxis table (with neutropenia [$< 0.5 \times 10^9$ neutrophils/l])

Diagnoses and therapies	Prophylaxis	Duration
Chronic lymphocytic leukaemia (CLL)	No prophylaxis	
CLL + geriatric or advanced and unresponsive disease or neutropenia > 6 months	± Prophylaxis	
Chronic myeloid leukaemia (CML). Tyrosine kinase inhibitor	No prophylaxis	
Lymphoma. No intensive chemotherapy	No prophylaxis	
Myelodysplastic syndrome. No intensive chemotherapy	No prophylaxis	
Myeloma	No prophylaxis	
Autologous HSCT with mucositis anticipated preengraftment	Fluconazole	From initiation to 7 days after resolution of neutropenia
Lymphoma. Intensive chemotherapy	Fluconazole	From initiation to 7 days after resolution of neutropenia
Solid tumour + mucositis anticipated for ≥ 7 days + neutropenia	Fluconazole	From initiation to 7 days after resolution of neutropenia
Acute myeloid leukaemia. Intensive chemotherapy	Posaconazole	From initiation to 7 days after resolution of neutropenia
Allogeneic HSCT	Posaconazole	Engraftment, or post HSCT day 75
Aplastic anaemia, severe	Posaconazole	From initiation to 7 days after resolution of neutropenia
Autologous HSCT; neutropenia > 14 days or slow engraftment anticipated or failure of engraftment	Posaconazole	Engraftment, or post HSCT day 75
CML. Intensive chemotherapy	Posaconazole	From initiation to 7 days after resolution of neutropenia
Graft versus host disease + prednisolone (or equivalent) ≥ 1 mg/kg per day for > 1 week + neutrophils $< 1 \times 10^9$ /l for > 1 week	Posaconazole	Graft versus host disease resolved, or prednisolone (or equivalent) < 10 mg/day
Graft versus host disease + prednisolone (or equivalent) ≥ 2 mg/kg per day for > 2 weeks	Posaconazole	Graft versus host disease resolved, or prednisolone (or equivalent) < 10 mg/day
Myelodysplastic syndrome. Intensive chemotherapy	Posaconazole	From initiation to 7 days after resolution of neutropenia
Acute lymphocytic leukaemia. Intensive chemotherapy	Ambisome®	From initiation to 7 days after resolution of neutropenia

Management of IFD: summary



References

Bennett, J. E., et al. 2015. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8th Edition. Elsevier.

British National Formulary. 2023. BNF.

Cornely, O. A., et al. 2014. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clinical Microbiology and Infection.

De Pauw, B., et al. 2008. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases.

Donnelly, J. P., et al. 2020. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium, Clinical Infectious Diseases.

Johns Hopkins ABX Guide. 2019. Cryptococcal Meningitis. Available at: [Cryptococcal Meningitis | Johns Hopkins ABX Guide \(hopkinsguides.com\)](https://www.hopkinsguides.com/hopkins/view/1111862125/9780781797914/cryptococcal_meningitis.html).

Maertens, J. A., et al. 2018. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. Journal of Antimicrobial Chemotherapy.

Pappas, P. G., et al. 2016. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases.

Sanford Guide Antimicrobial Therapy. 2022. Cryptococcosis. Available at: <https://www.sanfordguide.com/products/digital-subscriptions/>.

Schelenz, S., et al. 2015. British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. The Lancet.

The Renal Drug Database. 2019. The Renal Drug Handbook, 5th Edition. CRC Press.

Ullmann, A. J., et al. 2018. Diagnosis and management of *aspergillus* diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clinica Microbiology and Infection.

Wingard, J. R. 2021. Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients. UpToDate. Available at: [Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients - UpToDate](https://www.uptodate.com/contents/prophylaxis-of-invasive-fungal-infections-in-adult-hematopoietic-cell-transplant-recipients).

Wingard, J. R. 2022. Prophylaxis of invasive fungal infections in adults with hematologic malignancies. UpToDate. Available at: [Prophylaxis of invasive fungal infections in adults with hematologic malignancies - UpToDate](https://www.uptodate.com/contents/prophylaxis-of-invasive-fungal-infections-in-adults-with-hematologic-malignancies).

Document control

Development of guidelines:	Dr Ian Amott, Kayleigh Lehal, Dr Peter Slovak
Consultation with:	Haematology Consultant, Lead Antimicrobial Pharmacist, Microbiology Consultant
Version:	4
Approval date:	Antimicrobial Stewardship Group - 18/07/2023 CDCS Governance - 11/07/2023
Changes from previous version:	Introduction: reworded (minor). Primary prophylaxis: reworded (minor). Investigation: reworded (minor) and reformatted (minor). Criteria for diagnosis of IFD: reworded (minor) and reformatted (minor). Treatment of IFD: reworded (minor) and reformatted (minor). Management of <i>Candida</i> IFD: reworded (minor) and reformatted (minor). Management of <i>Cryptococcus</i> IFD: new. Management of <i>Aspergillus</i> IFD: reworded (minor) and reformatted (minor). Management of Mucorales IFD: reworded (minor) and reformatted (minor). Management of IFD: reworded (minor). Secondary prophylaxis: reworded (minor). Appendix: reworded (minor). References: updated (minor).
Date uploaded:	30/08/2023
Next review date:	September 2026
Key contacts:	Dr Peter Slovak, Microbiology Consultant p.slovak@nhs.net Kayleigh Lehal, Lead Antimicrobial Pharmacist kayleigh.lehal@nhs.net